PEN 221

Drug Profile

PEN 221

Alternative Names: BTP-227; PEN221

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator Tarveda Therapeutics
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Somatostatin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Neuroendocrine tumours; Small cell lung cancer

Most Recent Events

  • 09 Dec 2016 PEN 221 is available for licensing as of 09 Dec 2016. http://www.tarveda.com/about.html
  • 01 Nov 2016 Phase-I/II clinical trials in Neuroendocrine tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02936323)
  • 01 Nov 2016 Phase-I/II clinical trials in Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02936323)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top